Researchers compared total plasma pTau217 with a brain-derived pTau217 assay to determine which better identifies Alzheimer’s disease–related amyloid and tau pathology. Brain-derived pTau217 showed strong diagnostic performance and appeared less affected by kidney dysfunction, supporting its potential as a more specific blood biomarker for Alzheimer’s disease.